Metabolic dysfunction associated fatty liver disease in healthy weight individuals

Méndez-Sánchez N., Brouwer W. P., Lammert F., YILMAZ Y.

Hepatology International, cilt.18, sa.Suppl 2, ss.884-896, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: Suppl 2
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1007/s12072-024-10662-w
  • Dergi Adı: Hepatology International
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.884-896
  • Anahtar Kelimeler: Insulin resistance, Lipid metabolism, Liver fibrosis, MAFLD, MASLD, Metabolic dysfunction, NAFLD, NASH, Steatotic liver disease
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Evet

Özet

Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasing public health problem, affecting one third of the global population. Contrary to conventional wisdom, MAFLD is not exclusive to obese or overweight individuals. Epidemiological studies have revealed a remarkable prevalence among healthy weight individuals, leading investigations into the genetic, lifestyle, and dietary factors that contribute to the development of MAFLD in this population. This shift in perspective requires reconsideration of preventive strategies, diagnostic criteria and therapeutic approaches tailored to address the unique characteristics of MAFLD healthy weight individuals. It also underscores the importance of widespread awareness and education, within the medical community and among the general population, to promote a more inclusive understanding of liver metabolic disorders. With this review, we aim to provide a comprehensive exploration of MAFLD in healthy weight individuals, encompassing epidemiological, pathophysiological, and clinical aspects.